Image-guided dosimetry-based alpha particle therapy for neuroblastoma. - significance: neuroblastoma is the most common pediatric cancer, accounting for 15% of cancer deaths, with a 5-YR survival of…
Ended Project Grant Awarded Last action
- Award ID
- R44CA268314
- Recipient
-
Viewpoint Molecular Targeting, Inc. UEI RDZCK3F6AU73
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,932,125
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Iowa, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $961,450 | |
| Amendment | $990,225 | |
| Amendment | $990,225 | |
| Original award | $990,225 |
Quick answers
Who received award R44CA268314?
R44CA268314 was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on August 4, 2022.
How much is award R44CA268314 worth?
$3,932,125 has been obligated on R44CA268314.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award